ZyVersa Therapeutics, Inc.
ZVSA
$0.7899
-$0.0111-1.39%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -21.33M | -21.83M | -97.58M | -98.30M | -89.64M |
| Total Depreciation and Amortization | -98.80K | 18.20K | 10.40K | 10.40K | 126.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | 0.00 |
| Total Other Non-Cash Items | 12.70M | 12.69M | 87.62M | 86.97M | 74.88M |
| Change in Net Operating Assets | -391.90K | -288.40K | 2.04M | 2.60M | 4.89M |
| Cash from Operations | -9.12M | -9.41M | -7.91M | -8.72M | -9.74M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8.50M | 10.74M | 21.75M | 19.08M | 14.08M |
| Repurchase of Common Stock | 0.00 | 0.00 | -7.20K | -7.20K | -7.20K |
| Issuance of Preferred Stock | -- | -- | -- | -- | 548.80K |
| Repurchase of Preferred Stock | 0.00 | -230.00K | -10.70M | -10.70M | -10.70M |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -833.60K | -1.20M | -2.39M | -2.42M | -1.81M |
| Cash from Financing | 7.67M | 9.31M | 8.66M | 5.96M | 2.12M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash | -1.46M | -109.20K | 755.50K | -2.76M | -7.62M |
